共 25 条
[1]
Interleukin-11 modulates Th1/Th2 cytokine production from activated CD4+ T cells. Bozza M,Bliss JL,Dorner AJ,et al. Journal of Interferon and Cytokine Research . 2001
[2]
The immunologic basis for the treatment of psoriasis with new biologic agents. Krueger JG. Journal of the American Academy of Dermatology . 2002
[3]
Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Ogilvie AL,Antoni C,Dechant C,et al. Br J Dermatol . 2001
[4]
Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. Krueger JG,Walters IB,Miyazawa M,et al. Journal of the American Academy of Dermatology . 2000
[5]
Immunomodulation by interleukin-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in psoriasis. Friedrich M,Docke WD,Klein A,et al. Journal of Investigative Dermatology . 2002
[6]
A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB(389)IL-2) in patients with severe psoriasis. Martin A,Gutierrez E,Muglia J,et al. Journal of the American Academy of Dermatology . 2001
[7]
Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein. Zeltser R,Valle L,Tanck C,et al. Archives of Dermatology . 2001
[8]
Interleukin-11 inhibits macrophage interleukin-12 production. Leng SX,Elias JA. J Immunol . 1997
[9]
Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial. Asadullah K,Docke WD,Ebeling M,et al. Archives of Dermatology . 1999
[10]
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. Keane J,Gershon S,Wise RP,et al. The New England Journal of Medicine . 2001